Seres Therapeutics Receives Upgrade to Hold Rating

On Friday, analysts from StockNews.com upgraded Seres Therapeutics (NASDAQ:MCRB) moving their rating from "sell" to "hold" in their latest research report.

Recent assessments from other analysts have also impacted the perception of Seres Therapeutics in the market. JPMorgan Chase & Co. recently downgraded the company's stock from a "neutral" rating to an "underweight" status on October 24th. In contrast, Canaccord Genuity Group reaffirmed a "buy" rating, setting a price objective of $10.00 for the shares on November 14th. Additionally, Chardan Capital maintained a "buy" rating with a target price of $1.25 on November 13th. Currently, a mix of analysts have rated the stock: one has given a sell rating, two have assigned a hold rating, and two have designated it as a buy. According to MarketBeat, Seres Therapeutics holds an average rating of "hold" along with a consensus price target of $5.08.

Performance of Seres Therapeutics Stock

On Friday, shares of Seres Therapeutics experienced a slight drop of $0.01, trading at $0.83. During the session, 491,114 shares changed hands, which is below the average trading volume of 1,759,622 shares. The company holds a market capitalization of $142.17 million, with a PE ratio of -3.62 and a beta of 2.11. The stock's 50-day moving average is $0.85, while the 200-day moving average is $0.87. Over the past year, Seres Therapeutics has seen its stock price fluctuate between a low of $0.54 and a high of $1.53.

Institutional Holdings in Seres Therapeutics

Several institutional investors have recently adjusted their positions in Seres Therapeutics. During the fourth quarter, Jane Street Group LLC increased its holdings by 181.4%, now owning 58,736 shares worth approximately $49,000 after buying an additional 37,866 shares. Northern Trust Corp also boosted its stake by 20.4%, acquiring an additional 44,461 shares, leading to a total of 262,683 shares valued at $218,000. Geode Capital Management LLC raised its shares by 8.8%, now holding 1,510,432 shares worth $1,256,000. Meanwhile, Avantax Advisory Services Inc. grew its position by 170.9%, owning 45,179 shares worth $38,000 after adding 28,500 shares. Lastly, Charles Schwab Investment Management Inc. increased its stake by 15.6%, totaling 865,825 shares valued at $720,000. Currently, about 59.34% of the stocks are held by institutional investors and hedge funds.

Overview of Seres Therapeutics

Seres Therapeutics, Inc. is a biotechnology company focusing on developing microbiome therapeutics aimed at treating and modulating the colonic microbiome. The company specializes in creating a novel class of biological drugs that function by repairing a disrupted microbiome and restoring it to a healthy state.

Seres, Therapeutics, Hold